Qi ZENG

Institute of Molecular and Cell Biology, A*STAR, Singapore

Qi Zeng is presently Research Director at A*STAR’s Institute of Molecular Cell Biology (IMCB). She is also an Adjunct Professor at the Department of Biochemistry of the National University of Singapore (NUS). Zeng carried out her PhD research at Roswell Park Memorial Institute (RPMI, US) and IMCB (A-Star, Singapore) and was conferred her PhD degree by National University of Singapore (NUS) in 1993. Her team discovered PRL-3 and demonstrated that PRL1 and PRL3 monoclonal antibodies could inhibit experimental metastasis of cancer cells expressing these antigens. She proposed and pioneered an unconventional approach of immunotherapy targeting intracellular oncoproteins for inhibiting tumor growth in mouse models of cancer followed by preclinical studies. The IPs were licensed to IISG which has been sponsoring clinical trials of PRL3-zumab in solid cancers. The PRL3-zumabhas now been approved and currently ongoing in Phase 2 clinical trials in Singapore, US and China.